The precise origin of nasopharyngeal cancer remains unclear, but researchers have identified several contributing factors. One of the primary nasopharyngeal cancer causes is infection with the Epstein ...

Adjuvant therapy with camrelizumab significantly improved 3-year event-free survival in patients with locoregionally advanced nasopharyngeal carcinoma compared with observation, according to findings ...

Having frequent pain in the nose? It could actually be a sign of a rare form of cancer that has recently risen in numbers. While its place of origin is definitely a cause of worry, the fact that it is ...

In a phase 3 trial, toripalimab-based chemotherapy with radiotherapy without concurrent cisplatin achieved noninferior 3-year failure-free survival compared with standard therapy in patients with ...

Please provide your email address to receive an email when new articles are posted on . Researchers found nearly identical 3-year PFS data among the two cohorts. Grade 3 and 4 short-term toxic effects ...

Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell ...

Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous ...

The experimental nasal vaccine developed at Chiba University stimulated strong and long-lasting immune responses in animal models, activating tumor-fighting cells in the cervix and slowing cervical ...